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Abstract In more than 50% of patients with a mild-to-
moderate bleeding tendency, no underlying cause can be iden-
tified (bleeding of unknown cause, BUC). Data on parameters
of fibrinolysis in BUC are scarce in the literature and reveal
discrepant results. It was the aim of this study to investigate
increased fibrinolysis as a possible mechanism of BUC. We
included 270 patients (227 females, median age 44 years, 25–
75th percentile 32–58) with BUC and 98 healthy controls (65
females, median age 47 years, 25–75thpercentile 39–55).
Tissue plasminogen activator (tPA-) antigen and activity, plas-
minogen activator inhibitor type-1 (PAI-1), tPA-PAI-1 com-
plexes, thrombin activatable fibrinolysis inhibitor (TAFI), α2-
antiplasmin, and D-dimer were determined. While PAI-1 de-
ficiency was equally frequent in patients with BUC and
controls (91/270, 34%, and 33/98, 34%, p = 0.996), tPA ac-
tivity levels were more often above the detection limit in pa-
tients than in controls (103/213, 48%, and 23/98, 23%,
p < 0.0001). We found lower levels of tPA-PAI-1 complexes
(6.86 (3.99–10.00) and 9.11 (7.17–13.12), p < 0.001) and
higher activity of TAFI (18.61 (15.80–22.58) and 17.03
(14.02–20.02), p < 0.001) and α2-antiplasmin (102 (94–
109) and 98 (90–106], p = 0.003) in patients compared to
controls. Detectable tPA activity (OR 3.02, 95%CI 1.75–
5.23, p < 0.0001), higher levels of TAFI (OR 2.57, 95%CI
1.48–4.46, p = 0.0008) and α2-antiplasmin (OR 1.03, 95%CI
1.01–1.05, p = 0.011), and lower levels of tPA-PAI-1 com-
plexes (OR 0.90, 95%CI 0.86–0.95, p < 0.0001) were inde-
pendently associated with BUC in sex-adjusted logistic re-
gression analyses. We conclude that the fibrinolytic system
can play an etiological role for bleeding in patients with BUC.
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Plasminogen activator inhibitor-1 deficiency . Tissue
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Introduction
In the majority of adult patients with a mild-to-moderate
bleeding tendency, no diagnosis can be established and the
cause for the bleeding symptoms remains elusive [1]. This
lack of a diagnosis subsequently hinders targeted therapy
and causes high psychological strain in affected individuals
and treating physicians, especially in situations with increased
bleeding risk, such as surgery.
Fibrinolysis is a strictly regulated process modulated by
activators and inhibitors. Hyperfibrinolytic conditions associ-
ated with bleeding tendencies of variable severity have been
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found in hereditary deficiencies of anti-fibrinolytic factors,
such as α2-antiplasmin deficiency [2, 3] and deficiency of
the plasminogen activator inhibitor type-1 (PAI-1) [4–8].
Although hyperfibrinolysis has been discussed as a possible
cause for mild-to-moderate bleeding tendencies of unknown
cause, the assessment of fibrinolysis is not included in the
routine coagulation work-up of patients with mild-to-
moderate bleeding tendencies.
Parameters of fibrinolysis have been inconsistently inves-
tigated in few cohorts with a bleeding tendency and revealed
conflicting results [9–13]. Even the analysis of the same pa-
rameter in similar cohorts (e.g. patients with menorrhagia)
revealed discrepancies [13, 14].
Our study aimed to investigate fibrinolysis in a cohort of
patients with a mild-to-moderate bleeding tendency in whom
no diagnosis could be established despite thorough investiga-
tion of hemostatic parameters. We assessed a panel of factors
involved in the fibrinolytic process to determine the contribu-
tion of fibrinolysis to bleeding tendencies of unknown cause




All patients had symptoms of a mild-to-moderate bleeding
tendency that were recorded within the standardized question-
naire [15], encompassing skin manifestations such as hemato-
ma or easy bruising, increased postsurgical bleeding,
prolonged bleeding after tooth extraction, small wound bleed-
ing, epistaxis, oral mucosal bleeding, gastrointestinal bleeding
(not caused by pathologies in the GI-tract), spontaneous mus-
cle or joint bleeding, and heavy menstrual bleeding and in-
creased postpartum bleeding in females. For the current anal-
ysis, we selected patients with a mild-to-moderate bleeding
tendency in whom no diagnosis could be established from
two different bleeding cohorts: the Vienna Bleeding Study
(VIBS) and the Vienna Bleeding Biobank (VIBB). Both stud-
ies were conducted at the outpatient department of the
Division of Hematology and Hemostaseology, Medical
University Vienna, Austria and were approved by the Ethics
Committee of the Medical University Vienna. All procedures
were in accordancewith the ethical standards of the committee
on human experimentation (institutional and national) and
with the Helsinki Declaration of 1975, as revised in 2008.
All patients and controls gave their written informed consent.
For VIBS, patient recruitment started in November 2006
and was ongoing until March 2008. Patients who had been
investigated at our center in the years 2000–2004 because of a
mild-to-moderate bleeding tendency and in whom no diagno-
sis that would explain the bleeding tendency was established
were asked to participate in the study [16, 17]. The second
cohort (VIBB) started in 2009 and included all patients with a
mild-to-moderate bleeding tendency who were referred to the
outpatient department for further investigations. A cohort of
98 unrelated subjects without a history of bleeding and/or
thromboembolic events was recruited from hospital person-
nel, their friends, and relatives.
Patients and controls underwent a structured interview on
their medical history in general and their personal and familial
bleeding history in particular upon study inclusion.
Exclusion criteria that applied for patients and controls
were antithrombotic and/or anti-inflammatory therapy, im-
paired liver function (prothrombin time <75% of normal due
to a decrease in vitamin K dependent clotting factors), severe
renal insufficiency, and/or thrombocytopenia (<100 × 109/L).
Pregnant women, subjects with active malignancy, those with
surgery or delivery within 6 weeks, bacterial infection within
2 weeks prior to recruitment, or acute phase reaction at recruit-
ment were not included. Gastrointestinal (GI) bleeds due to
pathologies in the GI tract or intracerebral bleeding due to
aneurysm were not regarded as spontaneous bleeding.
Selection of patients with bleeding of unknown cause
(BUC)
Patients with vWF antigen and/or activity levels of ≤50%;
pathologies in the assessment of platelet function by light
transmission aggregometry and/or glycoprotein expression
by flow cytometry; deficiencies of the clotting factors VIII,
IX, or XIII ≤50%; or the diagnosis of any other known
inherited or acquired coagulation disorder were not included
in this analysis. In the VIBS, as previously described, 135
patients were screened for eligibility [17]. Of them, 101 pa-
tients fulfilled the inclusion criteria and were enrolled in the
study. Finally, 74 patients (73%), in whom no diagnosis ac-
cording to the criteria could be established and the assessed
parameters of fibrinolysis were available, were included in
this data analysis. Until November 2013, 277 patients were
included in the VIBB. No bleeding disorder could be found in
196 patients (71%). Thus, 270 patients with BUC were iden-
tified in the two-patient cohorts with mild-to-moderate bleed-
ing tendencies. In the present case-control study, results were
compared to those of 98 unrelated healthy controls.
Evaluation of the bleeding severity in patients with BUC
A standardized questionnaire, previously described [15], was
completed by a trained physician within a structured patient
interview. The recorded bleeding symptoms were epistaxis,
hematoma/easy bruising, small wound bleeding, oral mucosal
and/or gingival bleeding, GI bleeding, postpartum bleeding,
muscle and/or joint bleeding, bleeding after tooth extraction,
postsurgical bleeding, and menorrhagia. All bleeding
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symptoms were scored according to their most severe occur-
rence. The applied bleeding score quantifies the individual
bleeding tendency on a scale from 0 to 30 points.
Sampling
Blood samples were drawn with a 21-gauge butterfly needle
(Greiner Bio-One, Kremsmuenster, Austria) by antecubital
venipuncture into a Vacuette tube (Greiner Bio-One,
Kremsmuenster, Austria) containing trisodium citrate (nine
parts of whole blood, one part of trisodium citrate 3.8%).
The tubes were transferred to the MedUni Wien Biobank, a
central ized sample handling and storage facil i ty
(www.biobank.at). Hence, all further processing steps oc-
curred according to the standard operating procedures in an
ISO 9001:2008 certified environment. In detail, platelet poor
plasma was prepared by centrifugation at 2000g for 15 min at
15 °C (Hettich Rotanta 460 Robotic, Tuttlingen, Germany)
and as a second step at 18,000g for 2 min (Eppendorf
5417R, Hamburg, Germany) and stored at <−70 °C.
Assessment of hyperfibrinolysis
The following parameters were investigated in patients and
controls: tPA antigen (U/mL) and activity (U/mL), PAI-1 an-
tigen (U/mL), tPA-PAI-1 complexes (ng/mL), TAFI (ng/mL),
α2-antiplasmin (%), fibrinogen Clauss (mg/dL), and D-dimer
(μg/mL).
Tissue plasminogen activator (tPA) antigen and activity
were assessed using a sandwich ELISA (tPA Actibind
ELISA, Technoclone, Vienna) in which tPA is bound with a
catching antibody that is not interfering with its functional
activity. Bound tPA antigen is quantified with a peroxidase-
labeled monoclonal antibody (mAB). tPA activity was deter-
mined using plasminogen, cyanogen bromide fragments of
fibrinogen, and a plasmin substrate.
The active PAI-1 antigen (U/mL) was measured using a
sandwich ELISA (PAI-1 Actibind ELISA, Technoclone,
Vienna, Austria).
tPA-PAI-1 complexes were determined by ELISA (tPA-
PAI-1 Complex ELISA Kit, Technoclone, Vienna, Austria)
based on catching the complexes with a mAB directed against
tPA. For quantification, a peroxidase-labeled mAB against
PAI-1 was used.
Themeasurement of TAFIwas based on a chromogenic assay
(Stachrom TAFI, Asnières sur Seine, France) in which TAFI is
first activated to TAFIa by a human-thrombin-rabbit-
thrombomodulin complex and then quantified after two
hydrolysation steps by measurement of discoloration at 405 nm.
The activity of α2-antiplasmin was determined by the
chromogenic STA Stachrom antiplasmin assay (Diagnostic
Stago, Asnieres, France). Measurement was performed on a
STA-R evolution (Diagnostic Stago, Asnieres, France) at the
Clinical Department of Laboratory Medicine.
Fibrinogen was quantitatively measured by the Clauss-
method at the Clinical Department of Laboratory Medicine
using an automated assay (STA Fibrinogen, Roche
Diagnostics and Diagnostica Stago, Asnières sur Seine,
France). This functional assay is based on clotting of citrated
plasma in presence of an excess of thrombin, which is inverse-
ly proportional to the fibrinogen concentration. The reagent
contains a heparin inhibitor. Tests were performed on the
STA-R (Diagnostica Stago, Asnières sur Seine, France).
The fibrinogen degradation product D-dimer was deter-
mined by an ELISA (Asserachrom D-Di, Diagnostica Stago,
Asnières sur Seine, France). Binding to a mouse-mAB is used
to immobilize D-dimer. A peroxidase-labeled rabbit mAB
against human fragment D was used for quantification.
Statistics
All variables representing fibrinolysis parameters are described
by their median (quartile) values. To achieve normal distribution
in case of right-skewed variables, log2-transformed values were
used for all statistical analyses. Group comparisons with respect
to the continuous variables were performed using the two-sample
t test. The variable tPA activity was compared using the non-
parametric Wilcoxon rank sum test. TheWilcoxon rank sum test
was also used to compare the assessed parameters of fibrinolysis
between patients with or without specific bleeding symptoms.
No correction for multiplicity was applied due to the exploratory
character of this study.
Due to the high proportion of tPA activity values close to
zero and below the sensitivity of the assay, tPA activity was
considered as a binary variable (0 U/mL vs >0 U/mL) within
the regression models. Univariate logistic regression models
as well as sex-adjusted logistic regression models were per-
formed to evaluate the strength of the fibrinolysis variables to
discriminate between patients and controls. Results of the lo-
gistic regression models are given by the estimated odds ratios
(OR) with 95% confidence intervals (CI) and p values. P
values <0.05 were considered statistically significant.
Results
Characteristics of patients and controls
Clinical and laboratory characteristics of patients with BUC and
controls are shown in Table 1. There was a female predominance
in our group of patients with BUC. Blood groups were available
for 245 patients (90.7%) and 97 healthy controls (99%). Blood
group O occurred with an equal frequency in patients (42.4%)
and controls (44.3%). There was also no difference in age or
body mass index (BMI) between the groups.
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Interestingly, patients had lower levels of hemoglobin. As this
difference could be due to the female predominance in the patient
group, we adjusted for sex, and indeed, then the difference dis-
appeared (p = 0.71) (data not shown). There was no difference in
platelet count or global clotting tests such as prothrombin time
(PT, %) and activated partial thromboplastin time (APTT, sec-
onds) between patients with BUC and controls.
Table 2 depicts the occurrence of each bleeding symptom
and the proportion of manifestations requiring medical inter-
vention at least once.
Parameters of fibrinolysis in patients and controls
Table 3 shows the results for the fibrinolytic parameters in
patients with BUC in comparison to healthy controls.
Patients had significantly higher tPA activity than healthy
controls. tPA activity was measurable (>0 U/mL) more fre-
quently in patients than in healthy controls. Levels of tPA-
PAI-1 complexes were lower in the group of patients with
BUC. Levels of fibrinolysis-inhibitors TAFI and α2-
antiplasmin were increased in the group of patients and also
fibrinogen was higher in patients with BUC in comparison to
healthy controls.
In logistic regression analyses, detectable tPA activity >0 U/
mL, low tPA-PAI-1 complexes, increased levels of TAFI, α2-
antiplasmin, and fibrinogen remained significantly associated
with BUC also after adjustment for sex (Table 4).
We analyzed the presence of PAI-1 deficiency defined as
plasma levels of PAI-1 antigen <1 U/mL, a cut-off level also
used by Agren et al. [9, 10], as possible cause for BUC. In our
population, PAI-1 deficiency occurred with equal frequency in
patients and controls (Table 3). Activity of α2-antiplasmin
Table 1 Clinical and laboratory
characteristics of patients and
controls
Patients (n = 270) Controls (n = 98)
Female, n (%)* 227 (84.1) 65 (66.3)
BG 0, n (%)a 104 (42.4) 43 (44.3)
Family history, n (%)b 75 (34.7)
Median (25–75 percentile) Median (25–75 percentile)
Age (years) 44 (32–58) 47 (39–55)
BMI (kg/m2) 23.7 (21.3–27.1) 23.8 (21.5–25.9)
Hemoglobin (g/dL)* 13.7 (12.8–14.5) 13.9 (13.2–14.9)
Platelet count (109/L) 244 (216–278) 248 (220–286)
PT (%) 116 (106–126) 114 (103–125)
APTT (sec) 35.2 (33.2–38.0) 35.5 (33.3–37.4)
Bleeding score 4 (3–6) –
BG blood group, BMI body mass index, PT prothrombin time, APTT activated partial thromboplastin time
*Statistically significant difference between the groups
a Available of 245 patients (90.7%) and 97 healthy controls (99.0%)
b Family history of bleeding available of 216 patients (80.0%)
Table 2 Occurrence of bleeding
symptoms and requirement for
medical interventions
Frequency Medical intervention required
N n % n %
Hematoma/easy bruising 270 176 65.2 12 6.8
Increased postsurgical bleedinga 251 145 57.8 79 54.5
Abnormal bleeding after tooth extractiona 239 88 36.8 18 20.5
Increased bleeding from small wounds 270 87 32.2 0 0
Epistaxis 270 73 27.0 25 34.2
Increased oral mucosal bleeding 270 32 11.9 0 0
Gastrointestinal bleeding 270 25 9.3 6 24.0
Muscle or joint bleeding 270 4 1.5 0 0
Menorrhagiab 227 147 64.7 90 61.2
Abnormal postpartum bleedinga,b 157 53 33.8 25 47.2
a Patients exposed to surgery or tooth extraction or delivery
bAll women
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below normal (<75%) was found in five study participants,
two patients, and three healthy controls. None of the patients
or healthy controls had levels of α2-antiplasmin below 60%.
There was no specific pattern of altered fibrinolysis that
would correlate with any of the bleeding symptoms. Patients
with skin manifestations had higher levels (median (IQR)) of
fibrinogen (330 (294–377) and 307 (266–364), p = 0.017) and
D-dimer (0.32 (0.20–0.48) and 0.23 (0.16–0.35), p = 0.003)
than patients without skin manifestations. Likewise, levels of
TAFI (19.86 (16.34–25.77) and 18.42 (15.49–21.88),
p = 0.023) and D-dimer (0.36 (0.22–0.62) and 0.25 (0.17–
0.41), p < 0.001) were increased in patients with prolonged
bleeding from small wounds compared to those without;
levels of TAFI were also increased in patients with patholog-
ical postsurgical bleeding compared to those with a normal
postsurgical course (19.60 (16.34–23.04) and 18.23 (15.20–
22.58), p = 0.043). There was no difference in the assessed
fibrinolytic factors between patients with or without increased
oral mucosal bleeding, GI bleeding, or prolonged bleeding
after tooth extraction. In females, we found no difference in
the parameters of fibrinolysis between patients with or without
heavy menstrual bleeding. Patients with a history of increased
postpartum bleeding had slightly lower levels of D-dimer
compared to those with a normal postpartum course (0.30
(0.20–0.47) and 0.37 (0.25–0.63), p = 0.047).
Discussion
We investigated a broad panel of parameters with pro- and
anti-fibrinolytic capacity to get a clearer picture about the
involvement of fibrinolysis in BUC. The results indicate alter-
ations in the fibrinolytic process as a cause for increased
bleeding in patients with BUC. Up to now, parameters in-
volved in the fibrinolytic process were examined only in small
patient cohorts with a bleeding tendency, and the results were
controversial [10–14, 18].
We found significantly increased tPA activity, lower levels
of tPA-PAI-1 complexes, and slightly but significantly in-
creased levels of TAFI, α2-antiplasmin, and fibrinogen in
our patients with BUC compared to the group of healthy con-
trols. These factors were also independently associated with
BUC in sex- adjusted logistic regression analyses.
Table 3 Parameters of
fibrinolysis in patients with BUC
and controls
Patients Controls p
Median (25–75 percentile) Median (25–75 percentile)
tPA antigen (U/mL)a,* 1.75 (1.10–2.65) 2.26 (1.34–3.76) 0.096
tPA activity (U/mL)a 0.00 (0.00–0.13) 0.00 (0.00–0.00) <0.001
PAI-1 antigen (U/mL)* 1.9 (0.7–5.1) 2.5 (0.5–6.5) 0.809
tPA-PAI-1 complex (ng/mL)a 6.86 (3.99–10.00) 9.11 (7.17–13.12) <0.001
TAFI (ng/mL)b,* 18.61 (15.80–22.58) 17.03 (14.02–20.02) <0.001
α2-antiplasmin (%) 102 (94–109) 98 (90–106) 0.003
Fibrinogen (mg/dL) 324 (281–375) 312 (261–343) 0.003
D-dimer (μg/mL)c,* 0.28 (0.18–0.47) 0.28 (0.19–0.40) 0.194
n (%) n (%) p
PAI-1 antigen <1 U/mL 91 (34) 33 (34) 0.996
tPA activity >0 U/mLa 103 (48) 23 (23) <0.0001
tPA tissue plasminogen activator, PAI-1 plasminogen activator inhibitor-1, TAFI thrombin activatable fibrinolysis
inhibitor
*log2 transformed variables used for the comparison between the groups
a Available of 213 (78.9%) patients
b Available of 263 (97.4%) patients
c Available of 262 (97.0%) patients
Table 4 Sex-adjusted logistic regression analyses of parameters of
fibrinolysis
OR 95%CI p
tPA antigen* 0.87 0.72–1.06 0.16
tPA activity >0 U/mL 3.02 1.75–5.23 <0.0001
PAI-1 antigen* 1.06 0.95–1.19 0.30
tPA-PAI-1 complex (ng/mL) 0.90 0.86–0.95 <0.0001
TAFI* 2.57 1.48–4.46 0.0008
α2-antiplasmin (%) 1.03 1.01–1.05 0.011
Fibrinogen (10 mg/dL) 1.04 1.00–1.08 0.030
D-dimer* 1.05 0.83–1.34 0.68
tPA tissue plasminogen activator, PAI-1 plasminogen activator inhibitor-
1, TAFI thrombin activatable fibrinolysis inhibitor
*log2-transformed
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Our findings of increased tPA activity and lower levels of tPA-
PAI-1 complexes may indicate an impaired inhibition of tPA by
PAI-1. This could result from a functional defect of one of the
ligands, as there was no difference in PAI-1 activity or tPA anti-
gen levels between patients and controls in our cohort. This
impaired inhibition of tPA could result in higher fibrinolytic ac-
tivity and thus be responsible for the bleeding tendency in our
patients with BUC. To the best of our knowledge, we are the first
to investigate tPA activity in patients with a bleeding tendency, as
previous studies only investigated tPA antigen levels [10, 13, 14].
Likewise, quantitative measurements of tPA-PAI-1 complex
levels were only performed in a small number of studies on
patients with a bleeding tendency and results are inconclusive
[10, 12, 18]. In line with our data, one study reported lower
preoperative tPA-PAI-1 complex levels in association with in-
creased bleeding after cardiac surgery [12].
Levels of TAFI and α2-antiplasmin and fibrinogen were
slightly, but significantly increased in our patients with BUC
compared to controls and remained significantly associated with
BUC after adjustment for sex. This increase in anti-fibrinolytic
factors is surprising and difficult to explain. Still, it was the most
consistent finding when patients with a bleeding tendency were
compared to control individuals. In line with our data, increased
levels of TAFI andα2-antiplasmin have been reported in women
with strong menstrual bleeding [14]. High TAFI levels have also
been associated with a more severe bleeding phenotype in pa-
tients with hemophilia A and in patients with hereditary muco-
cutaneous hemorrhages [10, 11]. In the latter studies, α2-
antiplasmin was not investigated. This increased anti-
fibrinolytic capacitymight balance the augmented profibrinolytic
activity of tPA depicting the steady state in patients with BUC,
which prevents spontaneous and severe bleeding episodes.
Additional triggers, such as invasive procedures, minimal trau-
ma, or minor injuries, might tip this balance towards bleeding,
manifesting as a mild-to-moderate bleeding tendency.
We have previously shown that there was no difference in the
overall fibrinolytic capacity, represented by the half lysis time t50
in the turbidimetric assessment of plasma clot lysis between a
subgroup of our patients with BUC and controls. This finding is
in line with the results of Wiewel-Verschueren et al. [14] but in
contrast to the findings of Szczepaniak et al. [13], both studies on
patients with heavy menstrual bleeding. Overall fibrinolytic ca-
pacity is determined after addition of rtPA. This profibrinolytic
stimulus might mask subtle, but relevant differences of the fibri-
nolytic activity. Thus, the clot lysis time measured in plasma-
based assaysmight bemore an expression of a clot structure with
a higher susceptibility to fibrinolysis than an indicator of the
individual endogenous fibrinolytic potential.
Our study has several limitations. First, patients and controls
were of comparable age, but there was a female predominance in
the patient group. Still, the described differences in fibrinolysis
parameters remained statistically significant after adjustment for
sex. Second, the fibrinolytic activity follows a circadian variation,
with peak levels of PAI-1 and tPA antigen and the lowest tPA
activity in themorning [19].We considered that and restricted the
blood sampling time to 8.00–10.00 for both patients and controls.
Further limitations include pre-analytical factors in the determi-
nation of parameters of fibrinolysis. TPA activity has been re-
ported as unstable, especially in the presence of high PAI-1 levels
[20]. Thus, it has been recommended to determine fibrinolytic
variables, especially tPA, in samples of acidified citrated plasma
(Stabilyte™) [21–24], which inhibits tPA-PAI-1 complex forma-
tion and tPA inactivation [20, 25]. However, tPA-PAI-1 complex
levels in citrated plasma have been reported to be onlymarginally
increased [23]. Strengths of our study are the large number of
well-characterized patients with BUC, and the systematic inves-
tigation of multiple parameters known to regulate fibrinolysis.
In summary, we have measured a comprehensive panel of
parameters to assess fibrinolysis in a large cohort of patients
with a mild-to-moderate bleeding tendency of unknown
cause. We found alterations in fibrinolysis parameters, indi-
cating increased fibrinolytic activity, but also increased pro-
tection against fibrinolysis in patients with BUC in compari-
son to healthy controls. This observation is novel and might
depict the resting state of patients at risk for fibrinolytic bleed-
ing after hemostaseological challenges. The hypothesis of in-
creased fibrinolysis in patients with BUC is supported by the
clinical efficacy of anti-fibrinolytic agents, such as tranexamic
acid, in patients with mild bleeding symptoms [26–28]. We
could not confirm prior reports of PAI-1 deficiency [18] as a
risk factor for BUC in our cohort. Our data warrant further
studies to investigate and characterize the pathophysiological
processes underlying fibrinolysis in patients with BUC.
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